McLaughlin Asset Management Inc. Makes New $552,000 Investment in Merck & Co., Inc. $MRK

McLaughlin Asset Management Inc. purchased a new stake in shares of Merck & Co., Inc. (NYSE:MRK) during the fourth quarter, Holdings Channel.com reports. The firm purchased 5,241 shares of the company’s stock, valued at approximately $552,000.

A number of other large investors have also recently made changes to their positions in MRK. Kingdom Financial Group LLC. acquired a new stake in Merck & Co., Inc. during the 4th quarter worth about $25,000. Abound Financial LLC acquired a new position in shares of Merck & Co., Inc. in the fourth quarter valued at about $26,000. Prosperity Bancshares Inc acquired a new position in shares of Merck & Co., Inc. in the fourth quarter valued at about $26,000. United Financial Planning Group LLC purchased a new position in shares of Merck & Co., Inc. in the third quarter worth about $31,000. Finally, High Note Wealth LLC raised its stake in shares of Merck & Co., Inc. by 58.9% in the fourth quarter. High Note Wealth LLC now owns 294 shares of the company’s stock worth $31,000 after purchasing an additional 109 shares during the last quarter. 76.07% of the stock is owned by hedge funds and other institutional investors.

Merck & Co., Inc. Price Performance

Shares of NYSE MRK opened at $114.04 on Friday. The company has a debt-to-equity ratio of 1.02, a current ratio of 1.30 and a quick ratio of 1.06. The stock has a market capitalization of $281.65 billion, a price-to-earnings ratio of 32.12, a PEG ratio of 2.60 and a beta of 0.21. The firm’s 50 day simple moving average is $116.12 and its 200-day simple moving average is $113.60. Merck & Co., Inc. has a 12 month low of $76.66 and a 12 month high of $125.14.

Merck & Co., Inc. (NYSE:MRK) last posted its earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.47) by $0.19. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. The firm had revenue of $16.29 billion during the quarter, compared to analysts’ expectations of $15.85 billion. During the same period in the previous year, the business posted $2.22 EPS. The business’s revenue was up 4.9% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. Analysts expect that Merck & Co., Inc. will post 5.17 EPS for the current year.

Merck & Co., Inc. Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 8th. Shareholders of record on Monday, June 15th will be given a $0.85 dividend. The ex-dividend date is Monday, June 15th. This represents a $3.40 dividend on an annualized basis and a dividend yield of 3.0%. Merck & Co., Inc.’s dividend payout ratio is 95.77%.

Wall Street Analysts Forecast Growth

MRK has been the topic of several research reports. UBS Group increased their price target on shares of Merck & Co., Inc. from $130.00 to $145.00 and gave the stock a “buy” rating in a report on Monday, April 13th. Wall Street Zen upgraded shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating in a research note on Saturday, June 6th. Wells Fargo & Company dropped their price objective on shares of Merck & Co., Inc. from $150.00 to $145.00 and set an “overweight” rating on the stock in a report on Friday, May 1st. Zacks Research upgraded shares of Merck & Co., Inc. from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 17th. Finally, Citigroup began coverage on shares of Merck & Co., Inc. in a report on Wednesday, May 6th. They set a “neutral” rating and a $125.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and seven have issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $128.18.

Merck & Co., Inc. News Roundup

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: The U.S. FDA approved an additional indication for CAPVAXIVE, Merck’s pneumococcal vaccine, expanding its use to children and adolescents ages 2 through 17 at increased risk for pneumococcal disease. The expanded label could support longer-term sales growth and reinforces Merck’s vaccine franchise. Article Title
• Neutral Sentiment: Merck also announced broader corporate activity around AI drug discovery with Protillion Biosciences and a global HPV awareness campaign, which may help pipeline development and brand visibility over time but are not immediate revenue drivers. Article Title
• Neutral Sentiment: A separate survey from Merck Animal Health highlighted unmet needs in treating canine allergic skin disease, suggesting future product opportunity, but it is a relatively small and less immediate catalyst for the stock. Article Title
• Negative Sentiment: Despite the FDA win, MRK has still been trading lower recently, reflecting broader weakness in the shares and suggesting investors may be waiting for more evidence that new and existing products can offset slower growth in other parts of the portfolio. Article Title

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.